Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: Preliminary results

Neurological Research

Volumn 30, Issue 6, 2008, Pages 567-570

  Li, Shouwei ^b   Jiang, Tao ^a   Li, Guilin ^c   Wang, Zhongcheng ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Medical University   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Glioblastoma; MGMT; P53; Temozolomide

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; TEMOZOLOMIDE;

ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DRUG FORMULATION; FEMALE; FISHER EXACT TEST; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; NEUROLOGIC EXAMINATION; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; STUDENT T TEST; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR GROWTH;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MALE; MUTATION; RADIOTHERAPY; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 47749117161     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/174313208X297913     Document Type: Article

References (28)

1. Avgeropoulos NG, Batchelor TT. New treatment strategies for malignant gliomas. Oncologist 1999; 4: 209-224
2. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 30: 1323-1329
3. Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group Study. Cancer 1983; 52: 997-1007
4. Fischhaber PL, Gall AS, Duncan JA, et al. Direct demonstration in synthetic oligonucleotides that N,N-Bis(2-chloroethyl)-nitrosourea cross-links N1 of deoxyguanosine to N3 of deoxycytidine on opposite strands of Duplex DNA. Cancer Res 1999; 59: 4363-4368
5. Karran P, Hampson R. Genomic instability and tolerance to alkylating agents. Cancer Surv 1996; 28: 69-85
6. Jaeckle KA, Eyre HJ, Townsend JJ, et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitro-sourea: A Southwest Oncology Group Study. J Clin Oncol 1998; 16: 3310-3315
7. 6-methylguanine- DNA methyltransferase-deficient phenotype in human gliomas: Frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 1999; 5: 807-814
8. Nutt CL, Noble M, Chambers AF, et al. Differential expression of drug resistance genes and chemosensitivity in glial cell lineagescorrelate with differential response of oligodendrogliomas and astrocytomas to chemotherapy. Cancer Res 2000; 60: 4812-4818
9. 6-methylguanine-DNA methyltransferase gene. Cancer Res 1996; 56: 2029-2032
10. Tentori L, Lacal PM, Benincasa E, et al. Role of wild-type p53 on the antineoplasticactivity of TMZ alone of combined with inhibitors of poly(ADP-Ribose) polymerase. J Pharmacol Exp Ther 1998; 285: 884-893
11. Middlemas DS, Stewart CF, Kirstein MN, et al. Biochemical correlates of TMZ sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 2000; 6: 998-1007
12. Walker DR, Bond JP, Tarone RE, et al. Evolutionary conservation and somatic mutation hotspot maps of p53: Correlation with p53 protein structural and functional features. Oncogene 1999; 19: 211-218
13. D'Atri S, Tentori L, Lacal PM, et al. Involvement of the mismatch repair system in TMZ-induced apoptosis. Mol Pharmacol 1998; 54: 334-341
14. Dinapoli RP, Brown LD, Arusell RM, et al. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J Clin Oncol 1993; 11: 1316-1321
15. Eliott TE, Dinapoli RP, O'Fallon JR, et al. Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma. J Neurooncol 1997; 33: 239-250
16. Buckner JC, Schomberg PJ, McGinnis WL, et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer 2001; 92: 420-433
17. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979; 5: 1725-1731
18. Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 1991; 64: 769-774
19. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303: 1323-1329
20. Medical Research Council Brain Tumour Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council Trial. J Clin Oncol 2001; 19: 509-518
21. Grossman SA, O'Neill A, Grunner M, et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial gliobasltoma multifrome: Eastern Cooperative Oncology Group trial 2394. J Clin Oncol 2003; 21: 1485-1491
22. Fine HA, Dear KB, Loeffler JS, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71: 2585-2597
23. Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-1018
24. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992; 65: 287-291
25. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996
26. Dhodapkar M, Rubin J, Reid JM, et al. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 1997; 3: 1093-1100
27. Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendro-gliomas after standard radiotherapy and chemotherapy. J Clin Oncol 2001; 19: 2449-2455
28. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588-593